Wockhardt's New Facility Hit with 9 FDA Observations; CEO Promises Quick Resolution

Source: BusinessWorld

Jan 19, 2016

The U.S. FDA made nine observations highlighting manufacturing violations following inspection of Wockhardt's new sterile injectable drugs facility in Shendra, Aurangabad.

Wockhardt CEO Habil Khorakiwala did not disclose the specifics on the violations, but told the media the observations are not critical in nature and will be resolved in the next 2-3 months.

The facility, touted by the Indian drugmaker as "the first of its kind in Asia" was designed to produce difficult-to-manufacture injectable products. The facility is currently supplying to markets in the UK and Ireland.

Read the BusinessWorld article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments